Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The FDA Maze

J Levy

    Cutis
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Developing new dermatologic drugs is costly and complex. This article clarifies the rigorous Food and Drug Administration (FDA) approval process for new pharmaceutical entities, enhancing dermatologist understanding.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors.

    BMJ (Clinical research ed.)·1995
    Same author

    Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects.

    Gut·1995
    Same author

    Parathyroid hormone decreases in vivo insulin effect on glucose utilization.

    Calcified tissue international·1995
    Same author

    Intrinsic defect in B cells of patients with hyper-immunoglobulin M syndrome.

    Clinical and diagnostic laboratory immunology·1995
    Same author

    Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymphoid tissues from patients with X-linked immunodeficiency with hyper-IgM. Abortive germinal center cell reaction and severe depletion of follicular dendritic cells.

    Journal of immunology (Baltimore, Md. : 1950)·1995
    Same author

    Adjuvant surgical and hormonal treatment of leiomyomatosis peritonealis disseminata. A case report.

    The Journal of reproductive medicine·1995
    Same journal

    Black Dots on the Scalp of a Child.

    Cutis·2026
    Same journal

    Psoriasis and Obesity: A Clinical Review of the Bidirectional Link and Management Implications.

    Cutis·2026
    Same journal

    Adalimumab in Lichen Planus: A Narrative Review of Treatment and Paradoxical Reactions.

    Cutis·2026
    Same journal

    The Future of Psoriasis Care.

    Cutis·2026
    Same journal

    Evaluating GPT-4o for Automated Classification of Skin Lesions Using the HAM10000 Dataset.

    Cutis·2026
    Same journal

    Metastatic Primary Extramammary Paget Disease: A Case Series.

    Cutis·2026
    See all related articles

    Area of Science:

    • Dermatology
    • Pharmaceutical Sciences
    • Regulatory Affairs

    Background:

    • Developing new dermatologic pharmaceutical formulations requires extensive testing.
    • Regulatory submissions to the Food and Drug Administration (FDA) are detailed and involve negotiations.
    • Many dermatologists lack comprehensive knowledge of drug approval processes.

    Purpose of the Study:

    • To provide dermatologists with a clearer understanding of the procedures for obtaining FDA approval for new pharmaceutical entities.
    • To demystify the complex regulatory pathway for new dermatologic drugs.
    • To bridge the knowledge gap regarding drug safety and efficacy validation.

    Main Methods:

    • Review of FDA guidelines and regulatory submission requirements for pharmaceuticals.

    Related Experiment Videos

  • Analysis of the typical lifecycle of a dermatologic drug from development to approval.
  • Explanation of key stages in clinical trials and safety assessments.
  • Discussion of the negotiation process with regulatory bodies.

    • Main Results:

    • The FDA drug approval process involves multiple, stringent phases.
    • Successful navigation requires detailed documentation of safety and efficacy data.
    • Understanding these procedures is crucial for dermatologists involved in new drug evaluation.

    Conclusions:

    • A greater understanding of the FDA approval process can benefit dermatologists.
    • Streamlining comprehension of regulatory procedures aids in the evaluation of new dermatologic treatments.
    • This article serves as a guide to the complex journey of new pharmaceutical entities to market.